<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04796363</url>
  </required_header>
  <id_info>
    <org_study_id>Medical Research Institute</org_study_id>
    <nct_id>NCT04796363</nct_id>
  </id_info>
  <brief_title>US Guided Erector Spinae Plane Block in Breast Cancer Surgery: Analgesia, Spread and Immunomodulation</brief_title>
  <official_title>Ultrasound Guided Erector Spinae Plane Block in Breast Cancer Surgery: Analgesia, Spread and Immunomodulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexandria University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexandria University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective interventional study&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the present study is to evaluate the effect of US guided unilateral ESPB using&#xD;
      different volumes of local anaesthetics on analgesic efficacy, dermatomal spread and&#xD;
      immunomodulation in breast cancer surgery.&#xD;
&#xD;
      The primary outcome is the analgesic efficacy of the different local anaesthetic volumes of&#xD;
      ESPB.&#xD;
&#xD;
      The secondary outcomes are the dermatomal dye spread and sensory coverage, immunomodulation&#xD;
      and complications in breast cancer surgery.&#xD;
&#xD;
      Immunomodulation will be assessed by measuring Natural killer cells cytotoxicity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 25, 2020</start_date>
  <completion_date type="Anticipated">December 24, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 24, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Analgesic efficacy of ESPB</measure>
    <time_frame>Up to 24 postoperative hours</time_frame>
    <description>Analgesic efficacy of Erector Spinae plabe block by measuring visual analogue scale which ranges from 0 to 10. 0 indicates no pain and 10 indicates maximum imaginable pain</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Spread of the injected dye in Erector Spinae plane</measure>
    <time_frame>Patients will be imaged 15 minutes after the block and before induction of general anaesthesia and surgery.</time_frame>
    <description>5 ml of radio-contrast dye will be injected in Erector Spinae plane with different dose of Bupivacaine at the level of 4th thoracic vertebra then spread of the dye will be assessed by CT scan (for example dye spread to first thoracic vertebra level cranially and 9th thoracic vertebra caudally).&#xD;
3 D reconstruction of the image will be done then Craniocaudal spread of the contrast and spread to Paravertebral space, epidural space or rami of the spinal nerves will be assessed and recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dermatomal sensory coverage of ESPB</measure>
    <time_frame>Assessment will be done bilaterally every 3 minutes for 15 minutes after ESPB.</time_frame>
    <description>will be assessed by hyposthesia to cold sensation. Field of sensory block from T1 to T6 will be assessed bilaterally every 3 minutes for 15 minutes after deep ESPB using a piece of cotton soaked in iced water. The adequacy of sensory block T1-T6 will be determined before induction of general anaesthesia.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Immunomodulation of ESPB</measure>
    <time_frame>Before ESPB and 24 hours after the block.</time_frame>
    <description>Immunomodulation of ESPB by measuring Natural Killer cells cytotoxicity. Samples of 1 ml of patients' peripheral blood will be collected on EDTA for flow cytometry to enumerate for both cytotoxic lymphocyte populations (NK cells and cytotoxic t lymphocytes (Ctls)). CD 56 will be used as a marker for NK cells, while CD 8 will be used as a marker for Ctls.&#xD;
Cytotoxicity assay will be done by measuring the release of lactate dehydrogenase (LDH) from cells. Then ratio of LDH released specifically from NK cells will be correlated according to the results of flow cytometry.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Analgesia</condition>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>ESPB Bubivacaine 0.25%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 patients will receive US-guided deep ESPB block before induction of general anaesthesia using 20 ml bupivacaine 0.25 % and 5 ml of radiocontrast dye (Omnipaque) at the level of T4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ESPB Bubivacaine 0.125%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 patients will receive US-guided deep ESPB block before induction of general anaesthesia using 40 ml bupivacaine 0.125 % and 5 ml of radiocontrast dye (Omnipaque) at the level of T4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No ESPB</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>20 patients will undergo standard general anaesthesia as a control group and postoperative analgesia with intravenous morphine patient controlled analgesia (PCA) and rescue analgesia if required.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Erector Spinae Plane Block with Bubivacaine</intervention_name>
    <description>Erector Spinae Plane Block with Bubivacaine 0.25% or 0.125% before breast cancer surgery</description>
    <arm_group_label>ESPB Bubivacaine 0.125%</arm_group_label>
    <arm_group_label>ESPB Bubivacaine 0.25%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Standard General Anaesthesia</intervention_name>
    <description>Standard General Anaesthesia without ESPB</description>
    <arm_group_label>No ESPB</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:ASA physical status 1 or 2 scheduled for mastectomy under the effect of&#xD;
        General Anaesthesia&#xD;
&#xD;
        -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient refusal.&#xD;
&#xD;
          2. Allergy or contraindication to any of the studied medications or anaesthetic agents.&#xD;
&#xD;
          3. Chronic opioid analgesic use.&#xD;
&#xD;
          4. Pregnancy.&#xD;
&#xD;
          5. Morbid obesity (BMI â‰¥ 40 kg/m2).&#xD;
&#xD;
          6. Scoliosis or any vertebral anomalies or previous spinal surgeries.&#xD;
&#xD;
          7. Infection at the site of injection or any other contraindication for regional&#xD;
             anaesthesia.&#xD;
&#xD;
          8. Duration of surgery more than 90 minutes.&#xD;
&#xD;
          9. Renal impairment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emad Eldin Abd El Monem Arida, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>University of Alexandria</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical Research Institute, Alexandria University</name>
      <address>
        <city>Alexandria</city>
        <zip>21561</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>November 24, 2020</study_first_submitted>
  <study_first_submitted_qc>March 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2021</study_first_posted>
  <last_update_submitted>March 11, 2021</last_update_submitted>
  <last_update_submitted_qc>March 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Alexandria University</investigator_affiliation>
    <investigator_full_name>Ahmed Mohamed Mohamed Rabah Abdella</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>Erector spinae plane block</keyword>
  <keyword>Ultrasound guided</keyword>
  <keyword>Breast cancer surgery</keyword>
  <keyword>Natural killer cells</keyword>
  <keyword>Analgesia</keyword>
  <keyword>spread</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All IPD that underlie results in a publication</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>starting 6 months after publication</ipd_time_frame>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 23, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/63/NCT04796363/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

